AUS
NZ
UK
CA
USA
IND
Highlights:
- CSL has successfully completed the Vifor Pharma acquisition on 9 August 2022.
- The acquisition was initially announced on 14 December 2021.
- The shares of CSL are trading marginally in red today.
Australian healthcare giant CSL Limited (ASX:CSL) announced today that it has successfully completed acquiring Vifor Pharma acquisition on 9 August 2022.
Followed by this update on 10 August, the shares of CSL opened in red on the ASX. CSL’s share price was quoted 1.040% lower at AU$293.880 per share at 11:45 AM AEST on the ASX on Wednesday morning (10 August).
Details of CSL’s Vifor Pharma acquisition:
The acquisition of Vifor Pharma was initially announced on 14 December 2021, and it remained pending for a long time due to the lack of all the necessary regulatory approval.
On 2 August 2022, CSL announced that it had received all the regulatory approval needed for the acquisition to take place. Hence, on that day, CSL stated that it would complete the acquisition of Vifor by 9 August 2022.
As per the release on 2 August, CSL expected to hold more than 97% of Vifor shares upon completion and will intend to cancel the remaining publicly held Vifor shares, as per Swiss takeover rules.
Furthermore, the release also revealed that CSL would apply for the delisting of Vifor shares on the Swiss Exchange (SIX). In addition, CSL has already planned for the integration of Vifor.
What did the management of CSL say?
CSL ‘s share price performance on the ASX:
During the past one year, CSL’s share price has fallen 0.80% on the ASX. On year-to-date basis, CSL’s share price has fallen 1.09%. On the contrary, CSL’s share price has gained 15.39% in last six months on the ASX (as of 12:03 PM AEST).
